S Pfennig
The role of fatty acid hydrolase gene variants in inflammatory bowel disease
Storr M, Emmerdinger D, Diegelmann J, Yüce B, Pfennig S, Ochsenkühn T, Göke B, Lohse P, Brand S. The role of fatty acid hydrolase gene variants in inflammatory bowel disease. Aliment Pharmacol Ther 2008; 29:542-51.
02.12.2008The role of fatty acid hydrolase gene variants in inflammatory bowel disease
02.12.2008Aliment Pharmacol Ther 2008; 29:542-51
Storr M, Emmerdinger D, Diegelmann J, Yüce B, Pfennig S, Ochsenkühn T, Göke B, Lohse P, Brand Stephan
The role of the selenoprotein S (SELS) gene -105G>A promoter polymorphism in inflammatory bowel disease and regulation of SELS gene expression in intestinal inflammation
Seiderer J, Lohse P, Ochsenkühn T, Göke B, Haller D, Török H, Konrad A, Pfennig S, Kühnlein B, Dambacher J, Brand S. The role of the selenoprotein S (SELS) gene -105G>A promoter polymorphism in inflammatory bowel disease and regulation of SELS gene expression in intestinal inflammation. Tissue Antigens 2007; 70:238-46.
01.09.2007The role of the selenoprotein S (SELS) gene -105G>A promoter polymorphism in inflammatory bowel disease and regulation of SELS gene expression in intestinal inflammation
01.09.2007Tissue Antigens 2007; 70:238-46
Seiderer J, Lohse P, Ochsenkühn T, Göke B, Haller D, Török H-P, Konrad A, Pfennig S, Kühnlein B, Dambacher J, Brand Stephan
Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study
Seiderer J, Brand S, Dambacher J, Pfennig S, Jürgens M, Göke B, Ochsenkühn T. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther 2007; 25:787-96.
01.04.2007Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study
01.04.2007Aliment Pharmacol Ther 2007; 25:787-96
Seiderer J, Brand Stephan, Dambacher J, Pfennig S, Jürgens M, Göke B, Ochsenkühn T
The +1059G/C polymorphism in the C-reactive protein (CRP) gene is associated with involvement of the terminal ileum and decreased serum CRP levels in patients with Crohn's disease
Thalmaier D, Lohse P, Ochsenkühn T, Göke B, Crispin A, Otte J, Pfennig S, Schachinger V, Konrad A, Seiderer J, Dambacher J, Brand S. The +1059G/C polymorphism in the C-reactive protein (CRP) gene is associated with involvement of the terminal ileum and decreased serum CRP levels in patients with Crohn's disease. Aliment Pharmacol Ther 2006; 24:1105-15.
01.10.2006The +1059G/C polymorphism in the C-reactive protein (CRP) gene is associated with involvement of the terminal ileum and decreased serum CRP levels in patients with Crohn's disease
01.10.2006Aliment Pharmacol Ther 2006; 24:1105-15
Thalmaier D, Lohse P, Ochsenkühn T, Göke B, Crispin A, Otte J-M, Pfennig S, Schachinger V, Konrad A, Seiderer J, Dambacher J, Brand Stephan